These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37962220)

  • 1. Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.
    Kähler KC; Debus D; Schley G; Göppner D; Hassel JC; Meier F; Terheyden P; Stadler R; Tüting T; Kaatz M; Hoff NP; Masoudi E; Zdanowicz-Specht A; Nguyen MT; Mohr P
    Melanoma Res; 2024 Feb; 34(1):44-53. PubMed ID: 37962220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
    Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
    Dummer R; Queirolo P; Abajo Guijarro AM; Hu Y; Wang D; de Azevedo SJ; Robert C; Ascierto PA; Chiarion-Sileni V; Pronzato P; Spagnolo F; Mujika Eizmendi K; Liszkay G; de la Cruz Merino L; Tawbi H
    Lancet Oncol; 2022 Sep; 23(9):1145-1155. PubMed ID: 35940183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
    Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
    Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF
    Gutzmer R; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Manikhas GM; Yan Y; Huang KC; Uyei A; McNally V; McArthur GA; Ascierto PA
    Lancet; 2020 Jun; 395(10240):1835-1844. PubMed ID: 32534646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in
    Ribas A; Daud A; Pavlick AC; Gonzalez R; Lewis KD; Hamid O; Gajewski TF; Puzanov I; Wongchenko M; Rooney I; Hsu JJ; Yan Y; Park E; McArthur GA
    Clin Cancer Res; 2020 Jan; 26(1):46-53. PubMed ID: 31732523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
    Schmitt AM; Dumas L; Larkin J
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.
    Czirbesz K; Gorka E; Balatoni T; Pánczél G; Melegh K; Kovács P; Gézsi A; Liszkay G
    Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF
    Ascierto PA; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Zhukova N; Schachter J; Yan Y; Caro I; Hertig C; Xue C; Kusters L; McArthur GA; Gutzmer R
    Lancet Oncol; 2023 Jan; 24(1):33-44. PubMed ID: 36460017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, multicentre safety study of vemurafenib in patients with BRAF
    Larkin J; Brown MP; Arance AM; Hauschild A; Queirolo P; Vecchio MD; Ascierto PA; Krajsová I; Schachter J; Neyns B; Garbe C; Sileni VC; Mandalà M; Gogas H; Espinosa E; Hospers G; Lorigan P; Nyakas M; Guminski A; Liszkay G; Rutkowski P; Miller W; Donica M; Makrutzki M; Blank C
    Eur J Cancer; 2019 Jan; 107():175-185. PubMed ID: 30580112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
    Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
    Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
    N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF
    Blay JY; Cropet C; Mansard S; Loriot Y; De La Fouchardière C; Haroche J; Topart D; Tougeron D; You B; Italiano A; Le Brun-Ly V; Ferrero JM; Penel N; Fabbro M; Troussard X; Malka D; Ray-Coquard I; Leboulleux S; Fléchon A; Maubec E; Charles J; Dalle S; Taieb S; Garcia GCTE; Mandache AM; Colignon N; Gavrel M; Nowak F; Hoog Labouret N; Mahier Aït Oukhatar C; Gomez-Roca C
    ESMO Open; 2023 Dec; 8(6):102038. PubMed ID: 37922690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
    Sullivan RJ; Hamid O; Gonzalez R; Infante JR; Patel MR; Hodi FS; Lewis KD; Tawbi HA; Hernandez G; Wongchenko MJ; Chang Y; Roberts L; Ballinger M; Yan Y; Cha E; Hwu P
    Nat Med; 2019 Jun; 25(6):929-935. PubMed ID: 31171876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma.
    Eroglu Z; Chen YA; Smalley I; Li J; Markowitz JK; Brohl AS; Tetteh L; Taylor H; Sondak VK; Khushalani NI; Smalley KSM
    Cancer; 2024 Jan; 130(2):232-243. PubMed ID: 37776537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
    Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
    Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.
    Piejko K; Cybulska-Stopa B; Ziętek M; Dziura R; Galus Ł; Kempa-Kamińska N; Ziółkowska B; Rutkowska E; Kopciński T; Kubiatowski T; Bal W; Suwiński R; Mackiewicz J; Kamińska-Winciorek G; Czarnecka AM; Rutkowski P
    Target Oncol; 2023 Mar; 18(2):235-245. PubMed ID: 36906728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.